Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet"

• Hermans, W.R.M.
• Rensing, B.J.W.M.
• Strauss, B.H.
• Serruys, P.W.J.C.

January 1991
Article

Related Files
View PDF Version (eur_serruys_9023.pdf, 1.9MB)

• Male
• Animals
• Human
• Support, Non-U.S. Gov't
• *Angioplasty, Transluminal, Percutaneous Coronary
• Recurrence
• 0 (Calcium Channel Blockers)
• Platelet Aggregation Inhibitors/therapeutic use
• Anticoagulants/therapeutic use
• Anti-Inflammatory Agents/therapeutic use
• 0 (Anticoagulants)
• 0 (Anti-Inflammatory Agents)
• 0 (Antilipemic Agents)
• 0 (Growth Inhibitors)
• 0 (Platelet Aggregation Inhibitors)
• Antilipemic Agents/therapeutic use
• Calcium Channel Blockers/therapeutic use
• Coronary Arteriosclerosis/*prevention & control
• Growth Inhibitors/therapeutic use

• restenosi
• patient
• angioplasty
• group
• placebo
• angiography
• effect
• trial
• acetylsalicylic acid
• acetylsalicylic
• heparin
• platelet
• percutaneous transluminal
• muscle cells
• muscle
• cardiol
• follow-up
• factor
• artery
• transluminal